We have no way of knowing whether the data have integrity. The trials were poorly designed and the integrity of the data cannot be assumed. Dr. Kellmeyer is not going to move to New York from San Diego for $500K a year (a lot less than Missling was making) and an uncertain future. No. She came back as INTERIM CEO (not the permanent CEO) with a mission to sell the company. A merger with a similar-sized company that needs cash in an all stock deal is the only logical avenue to take. That is my opinion.